SkinBioTherapeutics Plc
SBTX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | – | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 94.1% | 43.1% | 934% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 59.7% | 55.6% | 52.1% | 64% |
| EBITDA | £0 | -£0 | -£0 | -£0 |
| % Margin | 21.5% | -55.9% | -126.7% | -1,278% |
| Net Income | £0 | -£0 | -£0 | -£0 |
| % Margin | 11% | -65.6% | -139.8% | -1,252.6% |
| EPS Diluted | 0.001 | -0.005 | -0.008 | -0.008 |
| % Growth | 128.3% | 41.8% | -5.3% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |